Danaher Corporation (DHR) is experiencing growth in diagnostics business through recent acquisitions

From Nasdaq: 2024-08-16 11:28:00

Danaher Corporation (DHR) is experiencing growth in its clinical diagnostics business, thanks to products like Aperio GT 450 DX and Access NT ProBNP. Recent acquisitions, like Abcam plc, have expanded DHR’s Life Sciences segment, boosting total revenues by 2% in the second quarter.

However, weakness in Danaher’s Instrument businesses is impacting its Life Sciences segment. High debt levels are also a concern, with long-term debt at $16.3 billion. The company is actively addressing these challenges while focusing on rewarding shareholders through dividends and share repurchases, recently increasing its dividend by 12.5%.

For investors looking at alternatives, Federal Signal Corporation (FSS), PDD Holdings Inc. (PDD), and 3M Company (MMM) offer better-ranked stock options. Federal Signal has a Zacks Rank of #1, while PDD Holdings and 3M carry a Zacks Rank of #2. These companies have shown positive performance with earnings surprises and increased 2024 earnings estimates.

For more in-depth stock analysis and recommendations, investors can access free stock analysis reports for 3M Company (MMM), Danaher Corporation (DHR), Federal Signal Corporation (FSS), and PDD Holdings Inc. Sponsored ADR (PDD) through the provided links. Visit Zacks.com for the latest insights and recommendations on these stocks.



Read more at Nasdaq: Danaher (DHR) Benefits From Business Strength Amid Risks